Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Oral Once-Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBV

Sunday, November 9, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the promising results of ALG-000184, an oral capsid assembly modulator, which has shown significant efficacy in suppressing HBV DNA levels in patients with chronic hepatitis B virus infection. This treatment is particularly noteworthy for both treatment-naive individuals and those not currently receiving treatment. The findings suggest a potential new avenue for managing chronic HBV.
Price reaction · baseline $7.07 (2025-11-07 close) · 1 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Demonstrates potent suppression of HBV DNA.
  • Effective in treatment-naive and currently-not-treated subjects.
  • Represents a novel approach to managing chronic HBV.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a novel oral capsid assembly modulator for treating chronic HBV.

Who can benefit from ALG-000184?

It is effective for treatment-naive patients and those not currently treated.

What does ALG-000184 do?

It demonstrates potent suppression of HBV DNA levels in affected individuals.

Is ALG-000184 a new treatment?

Yes, it represents a new approach in managing chronic hepatitis B.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 HBV chronic hepatitis B capsid assembly modulator treatment-naive
Last updated: Nov 9, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →